Cytotherapy

Article	Citations
Subscription information	69
Aims and Scope	60
Editorial Board	41
Immunotherapy: B7H3-CAR NK CELLS AND DNR CO-TRANSDUCED NK SHOWS MAINTAIN THEIR POTENCY AGAINST TGF-B MEDIATED IMMUNE SUPPRESSION	40
Immunotherapy: MULTI-CENTER GAMMA-DELTA T CELL CLINICAL TRIAL PRODUCT IDENTIFICATION USING NEW PRODUCT ATTRIBUTE AND NEW CODES FOR ISBT 128 LABELING	37
Mesenchymal Stem/Stromal Cells: HUMAN MSCS REDUCE INFLAMMATION AND PROMOTE REPAIR IN SEVERE HOUSE DIST MITE INDUCED ALLERGIC AIRWAY DISEASE DRIVEN BY MACROPHAGE MIGRATION INHIBITORY FACTOR	35
Embryonic, Organ and Other Tissue Specific Stem Cells: EXPLORING THE ANTI-TUMOR EFFECTS OF HUMAN WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELL SECRETOME ON PANCREATIC DUCTAL ADENOCARCINOMA CELLS IN CO	33
Exosomes/EVs: Late Breaking Abstract: EFFECTS OF AMNIOTIC FLUID DERIVED EXTRACELLULAR VESICLE BIOLOGIC ON T CELL PROLIFERATION AND ACTIVATION	32
CONSTRUCTION OF DEAD-CAS9 MACHINERY FOR ACTIVATION OF ENDOGENOUS NEUROPROTECTIVE TRANSCRIPTION FACTOR MAX IN VITRO	31
Immunotherapy: TARGETING EWING SARCOMA (ES), OSTEOSARCOMA (OS) AND NEUROBLASTOMA (NB) WITH ANTI-MCAM CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED NATURAL KILLER (NK) CELLS	28
iPSC: ENGINEERING 3D MICRO-COMPARTMENTS FOR HIGHLY EFFICIENT AND SCALE-INDEPENDENT EXPANSION OF HUMAN PLURIPOTENT STEM CELLS IN BIOREACTORS	28
Process Development and Manufacturing: CRYOPRESERVATION METHOD OPTIMIZATION FOR PLACE-OF-CARE MANUFACTURING OF A FIRST IN HUMAN TRI-SPECIFIC CAR T-CELL THERAPY PRODUCT FOR LYMPHOID MALIGNANCIES	27
GENERATION OF HUMAN INDUCED PLURIPOTENT STEM CELL LINES DERIVED FROM TWO BRAZILIAN PATIENTS WITH HUTCHINSON-GILFORD PROGERIA SYNDROME CARRYING C.1824 C>T MUTATION	27
Immunotherapy: EXPANSION AND PROCESSING OF A CLINICALLY RELEVANT NUMBER OF NK CELLS	27
Process Development and Manufacturing: VALIDATION OF THE MANUFACTURING OF AUTOLOGOUS MUC-1 ACTIVATED T CELLS FOR A PHASE I DOSE ESCALATION TRIAL FOR PATIENTS WITH MULTIPLE MYELOMA	27
THERAPEUTIC BENEFIT OF HUMAN WHARTON’S JELLY MESENCHYMAL STROMAL CELLS IN A MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS	26
Process Development and Manufacturing: CAR-T CELLS MANUFACTURED VIA POSITIVE AND NEGATIVE IMMUNOMAGNETIC T CELL SELECTION SHOW DIFFERENT TUMOR KILLING RATES, CYTOKINE PROFILES, AND γδ T CELL OUTPUT	25
GENERATION AND OPTIMIZATION OF ANTI-CD19 CAR-T CELL FOR LEUKEMIA IMMUNOTHERAPY	25
Mesenchymal Stem/Stromal Cells: HYPERINFLAMMATION AND IMMUNE CELL DYSREGULATION IN C7 HYPOMORPHIC MOUSE MODEL OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA: IMMUNE AND INFLAMMATION MODULATION BY HUMAN	24
Tissue Engineering: AUTOLOGOUS 3D NEURAL IMPLANTS FOR SPINAL CORD INJURY	24
Mesenchymal Stem/Stromal Cells: ICE RECRYSTALLIZATION INHIBITOR INCREASES POST-THAW FUNCTIONAL CAPACITY OF BONE MARROW AND UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS	24
Process Development and Manufacturing: IMPROVED DOWNSTREAM VIRUS PURIFICATION YIELD USING EXCIPIENT-GRADE RECOMBINANT ALBUMIN, EXBUMIN	23
Process Development and Manufacturing: A NEEDLE-BASED AUTOSAMPLER FOR BIOREACTOR CELL MEDIA COLLECTION	23
Mesenchymal Stem/Stromal Cells: SUBCUTANEOUS DELIVERY OF ALLOGENEIC INTERFERON-γ LICENSED BONE MARROW DERIVED MESENCHYMAL STROMAL CELL (IFN-γ MSC) FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY (TBI)	22
Hematopoietic Stem/Progenitor Cells and Engineering: HUMAN UMBILICAL CORD BLOOD DERIVED CELL THERAPY PRODUCT, DUOC-01, PROMOTES REMYELINATION BY DRIVING THE DIFFERENTIATION OF OPC	22

Process Development and Manufacturing: ONE YEAR FROM VECTOR TO BEDSIDE: RAMPING UP A SUCCESSFUL IN-HOUSE CAR T-CELL MANUFACTURING PROGRAM USING A NOVEL TRI-SPECIFIC CAR T-CELL THERAPY FOR LYMPHOID MAL	22
Immunotherapy: APPLICATIONS OF IMMUNE PROFILING: QUANTITATIVE PHENOTYPIC ANALYSIS OF ALS PATIENTS RECEIVING MSC THERAPY	22
Process Development and Manufacturing: MINIMIZING PARTICULATE CONTAMINATION IN SINGLE-USE SYSTEMS FOR BIOPHARMACEUTICAL AND PHARMACEUTICAL INDUSTRIES	21
Infusion reactions in natural killer cell immunotherapy: a retrospective review	20
Aims and Scope	20
Distinct effects of intravenous bone marrow-derived mesenchymal stem cell therapy on ischemic and non-ischemic lungs after ischemia-reperfusion injury	20
Regulatory advancements in Japan's conditional and time-limited approval scheme for regenerative medical products: the first guidance on the approval scheme and the second review for full approval of	20
Immunotherapy: A 3D VASCULARIZED MICROFLUIDIC MODEL OF THE TUMOUR MICROENVIRONMENT FOR ASSAYING PSC DERIVED CAR-T CELL FUNCTION	20
Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with “no-option” critical limb ischemia; observations on feasibility of the autologous approach from a clin	20
ESTABLISHING A NATIONAL REGULATORY POLICY AND FRAMEWORK FOR THERAPEUTIC USE OF CELL AND TISSUE THERAPIES IN SULTANATE OF OMAN.	19
COMPARATIVE PROFILING OF MESENCHYMAL STEM CELL EXTRACELLULAR VESICLES FOR APPLICATION IN REGENERATIVE DERMATOLOGY	19
INTER-DONOR VARIABILITY AND CELLULAR PROLIFERATION: THEIR IMPACT ON THE IMMUNOMODULATORY STRENGTH OF ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN T CELL-MEDIATED HEPATITIS	19
EFFECTS OF STORAGE TEMPERATURE ON VITAL PARAMETERS OF CLINICAL GRADE CRYOPRESERVED MESENCHYMAL STEM CELL FINAL PRODUCT	19
SAFETY AND EFFICACY RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF OCU400 MODIFIER GENE THERAPY FOR TREATMENT OF RETINITIS PIGMENTOSA	19
ECTOPIC EXPRESSION OF CD39, A KEY REGULATOR OF THE PURINERGIC SIGNALING PATHWAY, INCREASED THE IMMUNOMODULATORY PROPERTIES OF MSC-DERIVED EXTRACELLULAR VESICLES	19
FAPα-TARGETED IMMUNOTHERAPY WITH SIBROTUZUMAB AND HIGH AFFINITY FC-RECEPTOR EXPRESSING NK92 CELLS: A PROMISING APPROACH TO REVERSE FIBROSIS	18
MICROPOROUS PARTICLE SCAFFOLDS FOR MESENCHYMAL STROMAL CELL EXPANSION AND ENHANCED IMMUNOMODULATORY FUNCTION	18
SAMPLE TYPE, BUT NOT STORAGE DURATION, IMPACTS POST-THAW CD34 VIABILITY ON CORD BLOOD UNITS	18
CLINICALLY COMPLIANT MATRIX FOR HUMAN ES AND IPSC CULTURE FOR PRECLINICAL AND CLINICAL THERAPY	18
CARTAR WEB TOOL: A CASE STUDY UNVEILING PROMISING TARGETS FOR CHIMERIC ANTIGEN RECEPTOR THERAPIES IN COLORECTAL ADENOCARCINOMA	18
ANALYSIS OF COLD CHAIN PROCESSES FOR INVESTIGATIONAL CELL THERAPY PRODUCT SHIPMENTS AND TRANSPORT BASED ON REAL-WORLD TEMPERATURE DATA	18
OPTIMIZATION OF AUTOMATED SELECTION AND LENTIVIRAL VECTOR MEDIATED TRANSDUCTION OF MSC	18
Aims and Scope	18
International Society for Cell & Gene Therapy Expanded Access Working Group position paper: key considerations to support equitable and ethical expanded access to investigational cell- and gene-ba	17
Mesenchymal Stem/Stromal Cells: CELL CULTURE MEDIA (CCM) AND/OR LICENSING SIGNIFICANTLY AFFECTS THE GENE EXPRESSION, SECRETOME AND IMMUNE CELL INTERACTION CAPACITY OF UMBILICAL CORD DERIVED MESENCHYMA	17
Mesenchymal stromal cell therapy for coronavirus disease 2019: which? when? and how much?	17
Mesenchymal Stem/Stromal Cells: MULTIPOTENT MESENCHYMAL STROMAL CELLS FROM PATIENTS WITH SYSTEMIC SCLEROSIS HAVE PRESERVED CLONOGENICITY, IMMUNOPOTENCY AND IN VITRO ANTIFIBROTIC EFFECTS	17
INVESTIGATING THE INTERPLAY BETWEEN GUT MICROBIOME, MONOCYTES/MACROPHAGES, AND OSTEOARTHRITIS	17
Mesenchymal Stem/Stromal Cells: CAN PRIMING APPROACHES IMPROVE THE IMMUNOREGULATORY CAPABILITY OF HUMAN WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELLS TO TREAT PANCREATIC CANCER?	16
Exosomes/EVs: REAL-TIME BIOPROCESS MONITORING FOR LARGE-SCALE PRODUCTION OF MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES	16
THE EFFECT OF THE PRO-APOPTOTIC RHTRAIL PROTEIN IN THE PRESENCE OR ABSENCE OF THE COMBINATION WITH THE HSV-1 VIRUS IN HEAD AND NECK TUMOR LINES	16
Mesenchymal Stem/Stromal Cells: DEVELOPMENT OF ICH Q2 (R1) COMPLIANT IMMUNOPOTENCY ASSAY MEASURING MESENCHYMAL STROMAL CELLS MEDIATED T-CELL INHIBITION	16
Mesenchymal Stem/Stromal Cells: TRANSFECTION OPTIMIZATION FOR GENERATING CLINICAL GRADE IL-10 mRNA ENGINEERED MSCS	16
iPSC: IDENTIFICATION AND VALIDATION OF VENTRICULAR-SPECIFIC SURFACE MARKER FOR HUMAN PLURIPOTENT STEM CELLS-DERIVED CARDIOMYOCYTES	15
Mesenchymal Stem/Stromal Cells: EVALUATION OF SCALABLE ATTACHMENT-DEPENDENT EXPANSION SYSTEM FOR MESENCHYMAL STEM CELLS IN XENO- AND SERUM-FREE MEDIA	15
PREPARATION OF MUSCLE-DERIVED STEM CELLS SPHEROIDS IN A SCAFFOLD-FREE MICROMOLDED HYDROGEL MAINTAINING THEIR MYOGENIC POTENTIAL	15
Mesenchymal Stem/Stromal Cells: TARGETING ENDOGENOUS MESENCHYMAL STROMAL CELL RESPONSE TO INTERFERONγ IN SJÖGREN’S	15
Welcome to ISCT 2023	15
“Combined synergistic effects of concentrated growth factors and adipose-derived mesenchymal stem cells on regeneration of induced mandibular defects in rabbits”	15
Editorial Board	14
Consensus International Council for Commonality in Blood Banking Automation–International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin	14
ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy products	14
Programmed spontaneously beating cardiomyocytes in regenerative cardiology	14
Predicting chimeric antigen receptor apheresis process volume	14
Safety and Efficacy of High-Dose Memory CD45RO+ Donor Lymphocyte Infusion in Pediatric Recipients after Hematopoietic Stem Cell Transplantation	14
Mesenchymal Stem/Stromal Cells: CELLULAR AGING SECRETES: A COMPARISON OF BONE MARROW DERIVED AND INDUCED MESENCHYMAL STEM CELLS AND THEIR SECRETOME OVER LONG TERM CULTURE	14
Safety of allogeneic umbilical cord blood infusions for the treatment of neurological conditions: a systematic review of clinical studies	14
A Simple Approach to Monitor the Cryostorage of Hematopoietic Stem Cells	14
Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation	14
Proteomics profile of mesenchymal stromal cells and extracellular vesicles in normoxic and hypoxic conditions	14

Phospholipids in small extracellular vesicles: emerging regulators of neurodegenerative diseases and cancer	14
Volume determination methods for hematopoietic progenitor cell products collected by apheresis	14
Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity	14
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy	14
Advances in automated cell washing and concentration	14
The Impact of Prior Immunotherapy on Composition of Apheresis Material for CAR T-cell Therapy in Patients with B-Cell Acute Lymphocytic Leukemia (B-ALL)	13
Elevating MSC-EV Analysis: Development and Qualification of a CD73 Bioactivity Assay	13
2B4 inhibits the apoptosis of natural killer cells through phosphorylated extracellular signal-related kinase/B-cell lymphoma 2 signal pathway	13
A comprehensive review of quantum bioreactor cell manufacture: Research and clinical applications	13
Role of mesenchymal stromal cells derivatives in diabetic foot ulcers: a controlled randomized phase 1/2 clinical trial	13
Initial Experience Implementing a Structured Review Service for Non-GLP Study Data Intended to Support Regulatory Submissions at an Academic Institution	13
Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments	13
An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells (MSC) Committee perspectives on International Standards Organization/Technical Committee 276 Biobanking Standards for bone	13
Scalable Production of Hematopoietic Stem Cells and Microglia from iPSCs Using Stirred Tank Bioreactors for Consistent Cell Therapy Manufacturing	13
MOUSE MESENCHYMAL STROMAL CELL POTENCY ASSAY IN CONTEXT OF USE IN ACUTE LUNG INJURY	13
Impact of Age and acute GVHD on Thymic Reconstitution Post-HCT: Insights from Multicenter Immune Monitoring of Pediatric and Young Adult Patients	13
The hyper-inflammatory ARDS microenvironment enhances MSC reparative capacity in a pre-clinical model of acute lung inflammation	12
An innovative iPSC Reprogramming mRNA-LNP Kit for PBMC	12
CUTTING-EDGE LIPID-BASED MICROBUBBLE PLATFORM: ENHANCING CELL SORTING	12
Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors	12
A report on the International Society for Cell & Gene Therapy 2022 Scientific Signature Series, “Therapeutic advances with native and engineered human extracellular vesicles”	12
ACOUSTIC BEADS: A NOVEL METHOD FOR CELL SORTING USING ACOUSTOPHORESIS	12
Improving single cell multiomic analysis of T and B cells with innovations enhancing cost-effectiveness and data quality	12
Classification of Foreign Materials Found in Mesenchymal Stem/Stromal Cell Product Manufacturing	12
Enhancing Gene Transfer Efficiency in Viral and Non-Viral Vectors for Therapeutic Delivery	12
A Narrative Review of Islamic Bioethics and Regenerative Medicine: The Case of Amniotic Fluid Mesenchymal Stem Cells	12
Thymic Regulatory NK Cells: A Therapeutic Target for Restoring Immune Balance in Chronic Graft-Versus-Host Disease (cGVHD).	11
Repeated intravenous doses of human umbilical cord-derived mesenchymal stromal cells for bronchopulmonary dysplasia: results of a phase 1 clinical trial with 2-year follow-up	11
Human cornea-derived mesenchymal stromal cells inhibit T cells through indoleamine 2,3 dioxygenase	11
Gene Editing/Gene Therapies: A NOVEL WEIGHT-BASED APPROACH TO DETERMINE CELL TYPE SPECIFICITY FROM SINGLE CELL DATASETS	11
Streamlined Production of Tumor-Associated Antigen-Specific T Cells (TAAT) from Antigen-Naïve Donors in a GREX Device Using Autologous Monocyte-Derived Dendritic Cells (MoDC) Manufactured in the Same	11
Secretome of bone marrow mesenchymal stromal cells cultured in a dynamic system induces neuroprotection and modulates microglial responsiveness in an α-synuclein overexpression rat model	11
Immunotherapy: ALLOCETRA-OTS, AN EARLY APOPTOTIC CELLULAR THERAPY SYNERGIZE WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY OR IMMUNE CHECK POINT INHIBITOR AGAINST PERITONEAL SOLID TUMOR	11
Gene Editing/Gene Therapies: ENHANCING ANTI-OXIDATION OF MESENCHYMAL STROMAL/STEM CELLS USING CRISPR/CAS9 FOR INFLAMMATORY AND ISCHEMIC-REPERFUSION INJURY	11
Evaluating CAR T cell therapy processing with the Sefia™ expansion system using commercially available cell culture media	11
HYDROGEL MICROPARTICLE-BASED ARTIFICIAL ANTIGEN-PRESENTING CELL FOR EFFICIENT EXPANSION AND REACTIVATION OF NK CELLS EX VIVO.	11
EFFICIENT COST-EFFECTIVE MANUFACTURE OF A NON-VIRAL TRANSPOSON BASED NOVEL BAFF-CART FOR TREATMENT OF B-CELL CANCERS	11
Gene Editing/Gene Therapies: GDA-501 HER-2 CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELLS: DUAL CYTOTOXICITY IN SOLID TUMORS MEDIATED VIA HER2 AND TRAIL	11
Development of an induced pluripotent stem cell–specific microRNA assay for detection of residual undifferentiated cells in natural killer cell therapy products	11
Mesenchymal Stem/Stromal Cells: SUSPENSION CULTURE OF HUMAN MESENCHYMAL STROMAL CELLS ON DISSOLVABLE MICROCARRIERS IN AN ANIMAL COMPONENT FREE CULTURE SYSTEM	10
Immunotherapy: PHASE I CLINICAL TRIAL OF ANTI-MINOR HISTOCOMPATIBILITY ANTIGEN EXPANDED T CELLS TO TARGET LEUKEMIA RELAPSING AFTER ALLOGENEIC HLA-MATCHED TRANSPLANTATION	10
Immunotherapy: ANTI-GD2 CAR T CELLS AGAINST SMALL CELL LUNG CANCER	10
iPSC: THE IPS DERIVED MESENCHYMAL STEM CELLS AMELIORATED LIVER FIBROSIS AND LIVER FATTY DEPOSITION IN NAFLD/MAFLD-RELATED CIRRHOTIC MICE	10
Mesenchymal Stem/Stromal Cells: EVALUATION OF THE EFFECT OF MEDIUM COMPOSITION ON THE PHENOTYPIC AND FUNCTIONAL ATTRIBUTES OF MESENCHYMAL STROMAL CELLS	10
Tissue Engineering, Embryonic, Organ and Other Tissue Specific Stem Cells: GRAPHENE DERIVATES FOR BONE TISSUE REGENERATION	10
Tissue Engineering: DEVELOPMENT OF A TISSUE-ENGINEERED PRODUCT FOR GINGIVAL RECESSION	10
Mesenchymal Stem/Stromal Cells: INTRAVENOUS INJECTION OF XENOGENEIC MITOCHONDRIA ISOLATED FROM HUMAN FIBROBLAST AND MESENCHYMAL STEM/ STROMAL CELLS (MSC) ARE DETECTED IN THE HEART, INDUCE PGC-1α AND I	10
Mesenchymal Stem/Stromal Cells: MSC AND THEIR ISOLATED MITOCHONDRIA IMPROVE THE REGENERATION OF MICE CUTANEOUS SURGICAL WOUNDS BY IN-SITU INJECTION	10
Author index	10
Mesenchymal Stem/Stromal Cells: THE INTERFERON-GAMMA-INDOLEAMINE 2,3-DIOXYGENASE 1 (IFN-G-IDO1) AXIS IS NOT INVOLVED IN THE MSC-MEDIATED IMMUNOSUPPRESSION OF ACTIVATED T CELL PROLIFERATION	10
Mesenchymal Stem/Stromal Cells: TRANSCRIPTIONAL TARGETS OF TWIST1 IN HUMAN MESENCHYMAL STEM/STROMAL CELLS	10
Mesenchymal Stem/Stromal Cells: HUMAN MESENCHYMAL STEM CELL THERAPY IN SEVERE COVID-19 PATIENTS: 2-YEAR FOLLOW-UP RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	10
Process Development and Manufacturing: HIGH DENSITY BATCH CULTURES OF WJ-HMSCS IN STIRRED-TANK BIOREACTORS EQUIPPED WITH THE NOVEL BACH IMPELLER	9
Immunotherapy: THE BTLA-HVEM AXIS IS A CRUCIAL IMMUNE CHECKPOINT OF T CELL IMMUNOTHERAPIES FOR CANCER	9
Process Development and Manufacturing: SUPERIOR EXPANSION OF γδ T-CELL SUBSETS FOR SOLID TUMOR T-CELL THERAPY USING A CHEMICALLY-DEFINED NON-ANIMAL ORIGIN SERUM-FREE CULTURE MEDIUM	9
Immunotherapy: ACCELERATING DEVELOPMENT AND IMPROVING ACCESS TO CAR- AND TCR-ENGINEERED T CELL THERAPY IN EUROPE	9
Mesenchymal Stem/Stromal Cells: PATIENT RESPONSES TO MESENCHYMAL STROMAL CELL (MSC) THERAPY IN OSTEOARTHRITIS ARE ASSOCIATED WITH DIFFERENTIAL CLINICAL PHENOTYPES, MOLECULAR ENDOTYPES, AND MSC CRITICA	9
Mesenchymal Stem/Stromal Cells: SINGLE-CELL TRANSCRIPTOMICS COMPARISON OF CELL THERAPEUTICS IN OSTEOARTHRITIS	9
Exosomes/EVs: MSC-DERIVED EVS ATTENUATE ATOPIC DERMATITIS BY SUPPRESSING INFLAMMATION AND PROMOTING EPIDERMAL BARRIER REPAIR	9
Regulatory Affairs, Quality Systems, Policy, and Ethics: EVALUATION OF PERCENTAGE CHANGE IN PRE-DONATION AND POST-DONATION LABORATORY VALUES AFTER REPEATED (MNC), APHERESIS DONATIONS	9
Mesenchymal Stem/Stromal Cells: CELL CERAMTM ASSOCIATED WITH HUMAN LEVATOR VELI PALATINI MUSCLE STROMAL CELLS TO BONE RECONSTRUCTION IN CRANIOFACIAL SYNDROMES	9
Gene Editing/Gene Therapies: EVALUATION OF TRANSFECTION REAGENTS FOR HIGH TITER LENTIVIRUS PRODUCTION IN THE ICELLIS NANO BIOREACTOR	9
Mesenchymal Stem/Stromal Cells: IND CMC COMPATIBLE PURITY AND IDENTITY ASSESSMENT OF IFNγ-STIMULATED BONE MARROW SOURCED MESENCHYMAL STROMAL CELLS FOR A PHASE I CLINICAL TRIAL	9
Immunotherapy: CONVERTING IMMUNOLOGICALLY “COLD” MICROSATELLITE-STABLE COLORECTAL CANCER TO “HOT” BY DNA METHYLTRANSFERASE INHIBITOR AND RADIATION TO ENHANCE THERAPEUTIC EFFICACY	9
Mesenchymal Stem/Stromal Cells: UPFRONT USE OF ALLOGENEIC CYTO-MSC IMPROVES RESPONSE AND SURVIVAL RATES IN PATIENTS WITH ACUTE GVHD: AN INTERIM ANALYSIS OF ONGOING PHASE I/II MULTICENTER CLINICAL STUD	8
Mesenchymal Stem/Stromal Cells: EFFECTS OF COLD STORAGE ON MITOCHONDRIAL BIOENERGETICS AND PROTEIN IN HUMANMSCS	8
Subscription information	8
Predictive analytics and cord blood banking: toward utilization-based unit selection	8
AUTOANTIGEN-SPECIFIC REGULATORY T CELLS HALT THE PROGRESSION OF LUPUS NEPHRITIS	8
BACK TO BASICS: A SCIENTIFIC AND ECONOMIC EVALUATION OF ADHERENT AND SUSPENSION PROCESSING FOR AAV AT SCALE	8
Subscription information	8
Regulatory Affairs, Quality Systems, Policy, and Ethics: TESTING CELL THERAPY AND BIOPRODUCTION SAMPLES USING THE BIOFIRE® MYCOPLASMA MOLECULAR LAB IN A POUCH SYSTEM	8
Aims and Scope	8
Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the Eu	8
BIOMATERIAL-ENABLED MACROPHAGE CELL THERAPY VIA DEXAMETHASONE-LOADED MICROPARTICLES FOR REGENERATIVE MEDICINE	8
THE MULTI POTENTIALS OF PLACENTA CHORIODECIDUAL MEMBRANES-DERIVED-MSCS (PCMSCS) FOR DECIDUALIZATION AND ANGIO-MYOGENESIS	8
IMMUNOMODULATORY POTENTIAL OF EXTRACELLULAR VESICLES DERIVED FROM MESENCHYMAL STEM CELLS OBTAINED BY ULTRAFILTRATION AND ULTRACENTRIFUGATION	8
Removal of minute virus of mice-mock virus particles by nanofiltration of culture growth medium supplemented with 10% human platelet lysate	8
Perspectives on establishing a public cord blood inventory in South Africa	8
PROCESS DEVELOPMENT FOR SCALABLE ALLOGENEIC CAR-T MANUFACTURING IN STIRRED-TANK BIOREACTORS: PERFUSION OPTIMISATION, MULTI-LITRE SCALE-UP AND AUTOMATED HARVESTING	8

IMPLEMENTING CUSTOM PARTICLE SWARM-DIFFERENTIAL EVOLUTION OPTIMIZATION (PSODE) FOR GFP PLASMID DNA TRANSFECTION IN JURKAT AND PRIMARY T CELLS	8
A NEW ERA OF BIOLOGICS: THE ROLE OF SOUTH KOREA's REGULATORY SCIENCE CENTER IN ENSURING LONG TERM SAFETY	8
Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia	7
Scientific venturing for early-stage professionals (ESPs), a key concept in the innovation ecosystem	7
A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin	7
BIOPOTENCY AND SURROGATE ASSAYS TO VALIDATE IMMUNOMODULATORY POTENCY OF EXTRACELLULAR VESICLES DERIVED FROM MESENCHYMAL STEM/STROMAL CELLS	7
ABSOLUTE QUANTIFICATION OF GENOMIC TARGETS FOR CELL COUNTING USING DROPLET DIGITAL PCR	7
IMMUNOMODULATORY POTENTIAL OF ENHANCED MSC-DERIVED EXTRACELLULAR VESICLES	7
Impact of lower concentrations of dimethyl sulfoxide on cryopreservation of autologous hematopoietic stem cells: a systematic review and meta-analysis of controlled clinical studies	7
Impact of mesenchymal stromal/stem cell infusions on circulating inflammatory biomarkers in COVID-19 patients: analysis of a phase I-IIa trial	7
Advancing CAR-NK Cell Engineering by Overcoming Transduction Challenges	7
The peril of the promise of speculative cell banking: Statement from the ISCT Committee on the Ethics of Cell and Gene Therapy	7
Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies	7
Establishing a robust chimeric antigen receptor T-cell therapy program in Australia: the Royal Prince Alfred Hospital experience	7
MANUFACTURE OF A BANK OF “OFF-THE-SHELF” CD30.CAR-EBVSTS FOR THE TREATMENT OF LYMPHOMA	7
NON-VIRAL GENOME EDITING IN HEMATOPOIETIC STEM CELLS (HSCS) FOR CELL-THERAPY APPLICATIONS - FROM DISCOVERY TO MANUFACTURING	7
CD73 activity of mesenchymal stromal cell-derived extracellular vesicle preparations is detergent-resistant and does not correlate with immunomodulatory capabilities	7
2023 Gene Therapy Mini-Series	7
IMPROVED UNDERSTANDING OF CELL FATE USING A KIDNEY NORMOTHERMIC MACHINE PERFUSION MODEL	7
Reduced dimethyl sulfoxide concentrations successfully cryopreserve human hematopoietic stem cells with multi-lineage long-term engraftment ability in mice	7
Graft-versus-host disease is associated with skewed γδ T-cell clonality after umbilical cord blood transplantation in children with nonmalignant diseases	7
Three-dimensional cell culture of chimeric antigen receptor T cells originated from peripheral blood mononuclear cells towards cellular therapies	7
Mesenchymal stromal cells regulate THP-1–differentiated macrophage cytokine production by activating Akt/mammalian target of rapamycin complex 1 pathway	7
MULTIOMIC PROFILING OF EX VIVO EXPANDED CD45 (+)CD34(BRIGHT) CD38(-) CD90(+) CD49F(+)CELLS REVEALS NOVEL PATHWAYS FOR THE LONG-TERM MAINTENANCE OF HEMATOPOIETIC STEM AND PROGENITOR CELLS	7
INSIGHTS INTO SPATIOTEMPORAL DYNAMICS OF ALLOREACTIVE T CELL RESPONSE WITH γMSCS ADMINISTRATION	7
MESENCHYMAL STROMAL CELLS EXPRESSING DEGRON-HPV16 E5 AS A NOVEL CERVICAL CANCER VACCINE	7
Increasing access to transplantation through telemedicine and patient navigation	7
Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee	7
Dual-CAR NK cells targeting PD-L1 and ErbB2/HER2 eliminate solid tumor cells and prevent immune escape due to antigen loss	6
AdoShell®, a non-fibrotic encapsulation system for cell delivery	6
EFFECTS OF IGF-1-OVEREXPRESSING MESENCHYMAL STROMAL CELL TRANSPLANTATION IN A MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS	6
THE TETRAVECTA™ SYSTEM: A NEW TOOL KIT ENHANCING LENTIVIRAL VECTOR PRODUCTION FOR THE NEXT GENERATION OF GENE THERAPIES	6
The donor genetic determinant of human thymopoiesis rs2204985 is associated with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients	6
MICROFLUIDICS IMPROVES LENTIVIRUS TRANSDUCTION EFFICIENCY	6
Therapeutic Potential of First-Trimester Human Umbilical Cord Perivascular Cells in Mitigating Age-Related Muscle Dysfunction in a Natural Mouse Model of Aging	6
LONG-TERM TOLERANCE TO LEYDIG CELL TRANSPLANTATION WITH LOCALIZED TREG IMMUNOMODULATION USING THE NANOLYMPH PLATFORM	6
A Multi-Donor Characterization of Degradable Microscaffolds for Therapeutic T Cell Manufacturing	6
Detection of very small embryonic-like stem cells (VSELs) in the peripheral blood of rabbits subjected to induced retinal vein occlusion as a proposed early detection tool for the disease	6
Accelerating sterility testing: Symcel calScreener+ achieves results in <3 days with direct inoculation in non-destructive and continuous monitoring system	6
Results of the Phase I/IIb EXCELLENT trial evaluating the safety and efficacy of transendocardial injection of expanded autologous CD34+ cells in patients with recent myocardial infarction	6
STERILITY SAMPLING OF CELL, GENE, AND TISSUE THERAPY PRODUCTS (ATMPs)	6
Editorial Board	6
Filling the gap: the workforce of tomorrow for CGT manufacturing as the sector advances	6
PRE-CLINICAL CHARACTERIZATION OF ALLOCETRATM; A NOVEL MACROPHAGE REPROGRAMMING CELL THERAPY, FOR INTRA-ARTICULAR TREATMENT IN OSTEOARTHRITIS	6
Real World Experience of a Single-Center Tumor Infiltrating Lymphocyte (TIL) Melanoma Therapy Program: primary referral to TIL infusion (Brain to Vein)	6
Particulate Management in Bioprocessing: Challenges, Strategies, and Solutions	6
Advancing Wound Healing with Pre-Activated Umbilical Cord Mesenchymal Stem Cell Secretome	6
ENEPC-CLI-01- A PHASE 2 DOUBLE BLIND PLACEBO CONTROLLED STUDY FOR AUTOLOGOUS BGC-101, ENRICHED ENDOTHELIAL PROGENITOR CELLS, FOR CRITICAL LIMB THREATENING ISCHEMIA	6
ACTIVATION, EXPANSION, AND CULTURE OF HUMAN T CELLS INCORPORATING IMMUNOCULTTM CGMP-COMPLIANT ANCILLARY REAGENTS	6
CRISPR ENGINEERING OF ARMORED CAR T CELLS ENABLES TUMOR-RESTRICTED PAYLOAD DELIVERY WITH ENHANCED SAFETY AND EFFICACY	6
Allogeneic transplantation after immunotherapy for relapsed/refractory non-Hodgkin lymphoma: a comparison with a historical cohort	6
Challenging immunophenotyping of patients with sickle cell disease adversely affects gene therapy product manufacturing – case reports.	6
Investigating MSC immune suppressive function with quantitative phase microscopy and single-cell spatial lipidomics	6
EXPLORING INNOVATIVE BIOREACTOR SYSTEM FOR END-TO-END T CELL MANUFACTURING	6
THE ASSESSMENT OF WOMEN'S EDUCATION IN MEXICO ON CORD BLOOD (CB) BANKING AND ETHICAL IMPLICATIONS	6
Key Strategies for Successful Equipment Qualification in Cell Therapy GMP	6
Process Development and Manufacturing: CHALLENGES AND SOLUTION FOR PERFORMANCE VALIDATION OF EM AUTOMATION	5
Mesenchymal Stem/Stromal Cells: HIGH-DIMENSIONALL MULTI-OMICS COMPARISON OF CELLS IN BONE MARROW REVEALED ALTERATIONS TO IMMUNE CELLS IN OSTEOARTHRITIS	5
Human gingival mesenchymal stem cells improve movement disorders and tyrosine hydroxylase neuronal damage in Parkinson disease rats	5
Ex-vivo expanded CD34+ cell transplantation alleviates fibrotic liver injury via innate immune modulation in metabolic dysfunction-associated steatohepatitis mice	5
AGING OF MESENCHYMAL STEM CELLS IN VITRO: IMPLICATIONS IN PHENOTYPE AND DIFFERENTIATION CAPACITY	5
Tissue Engineering: AUTOFLUORESCENCE IMAGING IDENTIFIES KEY SUBSTRATE PROPERTIES TO SUPPORT STEM CELL-DERIVED CARDIOMYOCYTE DIFFERENTIATION	5
COMPARATIVE CHARACTERIZATION OF HUMAN DERMAL MESENCHYMAL STROMAL CELLS FROM DIFFERENT ANATOMICAL LOCATIONS AND ACROSS THE LIFESPAN	5
Gene Editing/Gene Therapies: EFFICIENT AND GENTLE NON-VIRAL ENGINEERING OF CELLS IN VITRO AND EX VIVO BY PHOTOPORATION	5
Immunotherapy: UTILIZATION OF BIDIRECTIONAL PROMOTERS IN SLEEPING BEAUTY-BASED DUAL CHIMERIC ANTIGEN RECEPTOR T CELL	5
Process Development and Manufacturing: EFFECT OF DONOR AND METHOD VARIABILITY ON BIOMANUFACTURING PROCESS ESTABLISHMENT	5
MINIMALLY INVASIVE TUMOR TISSUE PROCUREMENT IS FEASIBLE FOR CLINICAL MANUFACTURING OF OBX-115 ENGINEERED TUMOR-INFILTRATING LYMPHOCYTES (TIL)	5
Time course and mechanistic analysis of human umbilical cord perivascular cell mitigation of lipopolysaccharide-induced systemic and neurological inflammation	5
FTY720P-treated macrophages in PEG-4MAL hydrogels promote oral wound healing	5
Aims and Scope	5
EVALUATION OF IN VIVO TOXICITY OF CLINICAL-GRADE EXTRACELLULAR VESICLES DERIVED FROM HUMAN MESENCHYMAL STROMAL CELLS	5
The evolving regulatory system of advanced therapy medicinal products in China: a documentary analysis using the World Health Organization Global Benchmarking Tool standards	5
A machine-learning model that incorporates CD45 surface expression predicts hematopoietic progenitor cell recovery after freeze–thaw	5
INVESTIGATING THE ADVANCEMENTS IN MESENCHYMAL STEM CELLS AND THEIR SECRETOME: UNVEILING THE POTENTIAL FOR FACIAL REJUVENATION	5
Immunotherapy: INHOUSE MANUFACTURING OF CAR-T CELLS: MAKING QUALITY CAR-T CELL THERAPY MORE ACCESSIBLE TO THE GENERAL PUBLIC	5
Process Development and Manufacturing: C3P3-G3 ARTIFICIAL EXPRESSION SYSTEM FOR HIGH PERFORMANCE LENTIVIRUS PRODUCTION WITH IMPROVED PREDICTED BIOSAFETY	5
In-house abbreviated qualification of a real-time polymerase chain reaction method and strategies to amplify mycoplasma detection in human mesenchymal stromal cells	5
Gene Editing/Gene Therapies: MOVING THE NEEDLE FOR CELL THERAPIES: A NEXT-GENERATION EX VIVO PLATFORM USING NANONEEDLES FOR PRECISION CARGO DELIVERY	5
MULTIOMIC ANALYSIS OF γMSC-SUPPRESSED ALLOREACTIVE T CELLS	5
Regulatory Affairs, Quality Systems, Policy, and Ethics: VALIDATION AND COMPARISON OF AEROBIC AND ANAEROBIC BACTERIA, YEAST AND MOULD DETECTION USING THE BACT/ ALERT® 3D™ AND VIRTUO™ SYSTEMS FOR HAEMA	5
Living medicines: Training before handling	5
A systematic review of clinical trials for gene therapies for β-hemoglobinopathy around the world	5
Immunotherapy: IMPROVING CAR T CELL EFFICACY IN A PRECLINICAL MODEL OF BREAST CANCER THROUGH MODIFIED MANUFACTURING METHODS AND ADJUVANT THERAPY	5
Exosomes/EVs: Late Breaking Abstract: MSC-DERIVED EXTRACELLULAR VESICLES WITH ANTI-VIRAL EFFICACY ALLEVIATE VIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME	5
Immunotherapy: OFF-THE-SHELF PARTIAL HLA MATCHING SARS-COV-2 ANTIGEN SPECIFIC T CELL THERAPY: A NEW POSSIBILITY FOR COVID- 19 TREATMENT	5
Human platelet lysate enhances in vivo activity of CAR-Vδ2 T cells by reducing cellular senescence and apoptosis	5
VIABILITY, DIFFERENTIATION PROFILE AND GENIC EXPRESSION OF UMBILICAL CORD BLOOD HEMATOPOIETIC PROGENITOR CELLS CULTURED ON PLA/COL/HA/MSC-WJ CONSTRUCTS AS AN EX VIVO EXPANSION STRATEGY	5
A PLATFORM FOR THE ISOLATION AND CHARACTERIZATION OF EXTRACELLULAR VESICLES - EXPLORING A COMPREHENSIVE COLLECTION OF HUMAN EV	5
Embryonic, Organ and Other Tissue Specific Stem Cells: INFLAMMATORY CYTOKINE EFFECTS ON HEPATIC METABOLISM IN PRIMARY HUMAN HEPATOCYTES: A REVISED EVALUATION OF DONOR CELL FATE AFTER TRANSPLANTATION	5
Process Development and Manufacturing: ESTABLISHING CELL VIABILITY MEASUREMENTS THAT PREDICT PROLIFERATIVE CAPACITY IN A MODEL SYSTEM	5
Compliance and cost control for cryopreservation of cellular starting materials: An industry perspective	5
Immunotherapy: NK CELL EXPANSION USING SCALE UP BIOREACTORS FOR CELL THERAPY	5
Exosomes/EVs: GROWTH MEDIA CONDITIONS INFLUENCE THE SECRETION ROUTE AND RELEASE LEVELS OF ENGINEERED EXTRACELLULAR VESICLES	5
High-mobility group box 1 accelerates distraction osteogenesis healing via the recruitment of endogenous stem/progenitor cells	5
γδ T cells cultured with artificial antigen-presenting cells and IL-2 show long-term proliferation and enhanced effector functions compared with γδ T cells cultured with only IL-2 after stimulation wi	5